G6PD deficiency in malaria endemic areas of Nepal.
8-Aminoquinolines
G6PD deficiency
Malaria
Nepal
Plasmodium vivax
Primaquine
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
12 Aug 2020
12 Aug 2020
Historique:
received:
20
02
2020
accepted:
04
08
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is currently a threat to malaria elimination due to risk of primaquine-induced haemolysis in G6PD deficient individuals. The World Health Organization (WHO) recommends G6PD screening before providing primaquine as a radical treatment against vivax malaria. However, evidence regarding the prevalence and causing mutations of G6PD deficiency in Nepal is scarce. A cross-sectional, population-based, prevalence study was carried out from May to October 2016 in 12 malaria-endemic districts of Nepal. The screening survey included 4067 participants whose G6PD status was determined by G6PD Care Start™ rapid diagnostic test and genotyping. The prevalence of G6PD deficiency at the national level was 3.5% (4.1% among males and 2.1% among females). When analysed according to ethnic groups, G6PD deficiency was highest among the Janajati (6.2% overall, 17.6% in Mahatto, 7.7% in Chaudhary and 7.5% in Tharu) and low among Brahman and Chhetri (1.3%). District-wise, prevalence was highest in Banke (7.6%) and Chitwan (6.6%). Coimbra mutation (592 C>T) was found among 75.5% of the G6PD-deficient samples analysed and Mahidol (487 G>A) and Mediterranean (563 C>T) mutations were found in equal proportions in the remaining 24.5%. There was no specific geographic or ethnic distribution for the three mutations. This study has identified populations with moderate to high prevalence of G6PD deficiency which provides strong evidence supporting the WHO recommendations to screen G6PD deficiency at health facility level before the use of primaquine-based radical curative regimen for Plasmodium vivax.
Sections du résumé
BACKGROUND
BACKGROUND
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is currently a threat to malaria elimination due to risk of primaquine-induced haemolysis in G6PD deficient individuals. The World Health Organization (WHO) recommends G6PD screening before providing primaquine as a radical treatment against vivax malaria. However, evidence regarding the prevalence and causing mutations of G6PD deficiency in Nepal is scarce.
METHODS
METHODS
A cross-sectional, population-based, prevalence study was carried out from May to October 2016 in 12 malaria-endemic districts of Nepal. The screening survey included 4067 participants whose G6PD status was determined by G6PD Care Start™ rapid diagnostic test and genotyping.
RESULTS
RESULTS
The prevalence of G6PD deficiency at the national level was 3.5% (4.1% among males and 2.1% among females). When analysed according to ethnic groups, G6PD deficiency was highest among the Janajati (6.2% overall, 17.6% in Mahatto, 7.7% in Chaudhary and 7.5% in Tharu) and low among Brahman and Chhetri (1.3%). District-wise, prevalence was highest in Banke (7.6%) and Chitwan (6.6%). Coimbra mutation (592 C>T) was found among 75.5% of the G6PD-deficient samples analysed and Mahidol (487 G>A) and Mediterranean (563 C>T) mutations were found in equal proportions in the remaining 24.5%. There was no specific geographic or ethnic distribution for the three mutations.
CONCLUSIONS
CONCLUSIONS
This study has identified populations with moderate to high prevalence of G6PD deficiency which provides strong evidence supporting the WHO recommendations to screen G6PD deficiency at health facility level before the use of primaquine-based radical curative regimen for Plasmodium vivax.
Identifiants
pubmed: 32787970
doi: 10.1186/s12936-020-03359-6
pii: 10.1186/s12936-020-03359-6
pmc: PMC7425560
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287Références
J Histochem Cytochem. 2009 Nov;57(11):1003-11
pubmed: 19546473
Br J Haematol. 2014 Feb;164(4):469-80
pubmed: 24372186
Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78
pubmed: 19233695
Cardiovasc Hematol Disord Drug Targets. 2013 Mar 1;13(1):73-82
pubmed: 23534950
Gene Geogr. 1992 Dec;6(3):139-47
pubmed: 1339489
Malar J. 2013 Mar 27;12:112
pubmed: 23537118
Am J Hum Genet. 1991 Feb;48(2):390-7
pubmed: 1990845
Malar J. 2012 Dec 14;11:418
pubmed: 23237606
Indian J Pediatr. 2004 Jun;71(6):525-9
pubmed: 15226563
Adv Parasitol. 2013;81:133-201
pubmed: 23384623
Blood Cells Mol Dis. 2004 Sep-Oct;33(2):141-5
pubmed: 15315792
Malar J. 2014 Jun 23;13:241
pubmed: 24957851
J Hum Genet. 2004;49(10):544-547
pubmed: 15349799
Malar J. 2018 Mar 2;17(1):101
pubmed: 29499733
Ann Trop Med Parasitol. 2007 Mar;101(2):113-22
pubmed: 17316497
J Hum Genet. 2003;48(5):275-277
pubmed: 12768444
Hematol Oncol Clin North Am. 2016 Apr;30(2):373-93
pubmed: 27040960
Infect Genet Evol. 2010 Dec;10(8):1228-36
pubmed: 20713184
J Hum Genet. 2008;53(1):48-54
pubmed: 18046504
Trop Med Health. 2019 Mar 27;47:21
pubmed: 30976192
Hum Genet. 2001 Jun;108(6):445-9
pubmed: 11499668
Eur J Hum Genet. 2014 Dec;22(12):1404-12
pubmed: 24667789
J Pediatr Genet. 2019 Jun;8(2):47-53
pubmed: 31061745
Cochrane Database Syst Rev. 2015 Apr 29;(4):CD010458
pubmed: 25921416
Trans R Soc Trop Med Hyg. 1987;81(4):543
pubmed: 3445334
Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389
pubmed: 24163057
Malar J. 2014 Feb 25;13:70
pubmed: 24568147
Malar J. 2014 Nov 03;13:418
pubmed: 25363455
Malar J. 2019 Jan 23;18(1):20
pubmed: 30674319
Bull World Health Organ. 1966;35(6):837-56
pubmed: 5338376
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Malar J. 2017 May 23;16(1):214
pubmed: 28535765
Pharmacol Ther. 2016 May;161:1-10
pubmed: 27016470
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Malar J. 2017 Apr 5;16(1):141
pubmed: 28381261